【摘要】 目的:回顾性的讨论分析我中心S1节拍化疗联合多西他赛治疗晚期一线治疗失败的非小细胞肺癌病例。方法:收集2016年1月—2018年12月我院收治的48例接受口服S1节拍化疗联合多西他赛治疗晚期一线治疗失败的NSCLC的临床资料,进行回顾性分析。结果:中位随访时间为14(5～29)个月。患者的中位治疗周期数为2(1～8)个,无患者达到完全缓解,6例(12.5%)患者达部分缓解,20例(41.7%)达疾病稳定, 22例(45.8%)为疾病进展。患者的有效率为12.5%,疾病控制率为54.2%。中位疾病无进展时间(Progression-free survival, PFS)为4个月。治疗的耐受性一般,有严重毒性反应发生。结论:口服S1节拍化疗联合多西他赛可作为治疗晚期NSCLC选择性人群的治疗方案,但需要进一步探讨其最佳的使用剂量和联合方式。更多还原

【Abstract】 Objective:Retrospectively discussed and analyzed the cases of non-small cell lung cancer that failed first-line treatment in S1 metronomic chemotherapy combined with docetaxel in our center.Methods:Our retrospective study enrolled 48 patients who received metronomic oral S1 with conventional chemotherapy Survival factors were evaluated.Results:The median follow-up was 14(5～29) months.The median number of treatment cycles was 2(1～8),no patients achieved complete remission,6(12.5%) partial remission,20(41.7%) stable disease, and 22(45.8%) progression disease.Overall response rate was 12.5% and the disease control rate was 54.2%. The median progression-free survival(PFS) was 4 months. Treatment was tolerated with serious toxicity.Conclusion:Oral S1 metronomic chemotherapy combing with docetaxel can be used as a treatment regimen for patients with advanced NSCLC selectivity, but the optimal dosage and combination should be further explored.更多还原